Skip to main content
Season 3 ends in 25 d 11:42:26 $2,000 10,000 pts = 1 month Premium
Health & Medicine

Mounjaro Muscle Loss: Weight Training Helps, Trial Finds

Published 11 min read
Open the post and read it to claim 30 points
A dumbbell and a blue injection pen beside a glowing muscle illustration, representing Mounjaro muscle loss and weight training

Sign in and earn +30 points by reading this

Read to the end, wait a few seconds, then tap the claim button below.

In short

As of 13 November 2026, a randomised trial published in Nature Medicine on 9 November found that adults aged 50 to 70 taking tirzepatide (Mounjaro) who did supervised resistance training lost less lean tissue and gained strength, while those who did not lost strength [1][2]. Weight loss was similar in both groups [1].

Key takeaways

  1. The T-REx trial at the University of Western Australia gave 120 men and postmenopausal women aged 50 to 70 tirzepatide for 40 weeks, and randomly assigned half to supervised resistance training three times a week [1][2].
  2. Both groups lost about 22 kg on average: 22.61 kg without training and 22.28 kg with training [1].
  3. Lean soft tissue loss was 4.67 kg without training and 3.57 kg with training, a difference of 1.09 kg [1].
  4. Strength fell without training (for example −4.42 kg on knee extension) but rose with training (+5.88 kg) [1].
  5. Participants had no diabetes or cardiovascular disease and were sedentary at the start, so the results may not apply to everyone on tirzepatide, the authors say [1].
  6. Eli Lilly supplied tirzepatide and reviewed the protocol and a draft of the paper, but gave no other funding and had no role in running the trial, according to the paper [1].
On this page 10 sections
  1. Does Mounjaro cause muscle loss?
  2. What did the T-REx trial find?
  3. Who was in the Mounjaro muscle trial?
  4. What are the limits of the trial?
  5. Should people on Mounjaro do weight training?
  6. What comes next for GLP-1 drugs and muscle?
  7. Common mistakes
  8. Frequently asked questions
  9. Glossary
  10. Sources

Does Mounjaro cause muscle loss?

Mounjaro (tirzepatide) causes large weight loss that includes some lean tissue, which contains muscle; in the T-REx trial, people taking it without exercise training lost an average of 4.67 kg of lean soft tissue over 40 weeks [1].

The trial's authors write that incretin drugs such as tirzepatide "induce substantial weight and fat loss but also decrease lean soft tissue mass", the latter "possibly impairing skeletal muscle function" [1]. They note that loss of skeletal muscle predisposes older adults to sarcopenia and frailty [1].

  • Lean mass is not only muscle: the University of Western Australia explains that lean mass is body weight minus fat and includes muscles, organs, bones, skin and body water [2].
  • Some loss is expected with any weight loss: lead investigator Danny Green said loss of lean mass "is an inevitable part of weight loss by any method", including diet, exercise or surgery [2].
  • Measurement: the trial measured lean soft tissue with DXA scans, which cannot separate muscle from other lean tissue exactly [1].

The weight loss behind these concerns is large. In the SURMOUNT-1 trial of 2,539 adults with obesity, published in the New England Journal of Medicine in 2022, average weight fell by up to 20.9% over 72 weeks on the highest tirzepatide dose, against 3.1% on placebo [5]. That trial was funded by Eli Lilly [5].

The NHS describes tirzepatide as a GLP-1/GIP agonist, injected once a week, used for type 2 diabetes or obesity alongside diet and exercise changes [3].

A whole-body DXA scanner table in a clinic, the scan used to measure lean mass in the Mounjaro muscle trial
The trial measured fat and lean tissue with DXA body scans.

What did the T-REx trial find?

Resistance training reduced the loss of lean soft tissue by 1.09 kg and turned a loss of strength into a gain, without changing how much weight or fat people lost [1].

  • Weight: −22.61 kg on tirzepatide alone versus −22.28 kg with training; no significant difference [1].
  • Fat mass: −17.19 kg versus −17.98 kg; no significant difference [1].
  • Lean soft tissue: −4.67 kg versus −3.57 kg, a between-group difference of 1.09 kg (confidence interval 0.43 to 1.75 kg; the abstract labels it a 95% interval and the results section a 97.5% interval) [1].
  • Arms and legs (appendicular lean mass): −3.55 kg versus −2.92 kg [1].
  • Strength: without training, bench press fell 4.09 kg, lat pulldown 4.42 kg and knee extension 4.42 kg; with training they rose 4.68 kg, 8.58 kg and 5.88 kg [1].

The university summarised this as 25% less lean tissue loss in the training group, and strength improving by about 10% with training while falling by about 10% without it [2]. Adherence to the training sessions was 91%, and 93% of participants completed the trial [1].

Green told newsGP, the news service of the Royal Australian College of General Practitioners, that muscle loss was not completely prevented even with training, but that "the strength benefits are more important for outcomes like frailty, which we were concerned for" [4]. Body composition was scanned every eight weeks, and he said that muscle strength decreases in the first 16 weeks [4].

The table below sets out the main results.

A leg extension machine with a weight stack in a dark gym, representing knee strength testing in the tirzepatide trial
Knee extension strength rose 5.88 kg with training and fell 4.42 kg without it.

Who was in the Mounjaro muscle trial?

The single-centre trial, run by the University of Western Australia, enrolled 120 adults aged 50 to 70: 60 men and 60 postmenopausal women with obesity, or overweight with a weight-related condition, and without diabetes [1][2].

  • Age: mean 57.7 years (range 50.1 to 70.3) [1].
  • Weight category: 86.7% had obesity and 13.3% overweight [1].
  • Exclusions: no diabetes or cardiovascular disease, no cardiovascular medicines, and participants were sedentary at the start [1].
  • Groups: 61 took tirzepatide with usual activities; 59 took tirzepatide plus three supervised, centre-based progressive resistance sessions a week for 40 weeks [1].
  • Diet: all participants were told to maintain protein intake, with general advice on hydration, protein and fibre, but no specific diet programme [1][2].
  • Industry role: Eli Lilly reviewed the protocol, provided tirzepatide and reviewed a draft of the paper, but did not provide other funding or run the trial, the paper states; its competing-interests statement says some authors have received speaker honoraria from Eli Lilly [1].

Six participants withdrew because of adverse events, two because of a breast cancer diagnosis and one for personal reasons [1].

What are the limits of the trial?

The authors say the findings may not apply to everyone taking tirzepatide, because the trial enrolled sedentary 50- to 70-year-olds without diabetes or heart disease, and ran for only 40 weeks [1].

  • Small and specific: 120 participants, aged 50 to 70, from one centre [1].
  • Not blinded: participants knew whether they were exercising, and the exercise physiologists who tested strength could not be blinded to group; the DXA analyst was blinded, and DXA results are produced by software the authors call objective [1].
  • Lean mass versus muscle: DXA measures lean soft tissue, not muscle alone; about 15% of fat tissue is itself lean mass, so some lean loss is expected when fat is lost [1].
  • Real-world feasibility: sessions were supervised in a centre; the authors say feasibility "needs to be established in routine clinical practice" [1].
  • Long-term outcomes: further studies are needed to see how differences in lean mass affect long-term health [1].

Green told newsGP that the bigger worry is people in a "pre-frailty zone", because starting a GLP-1 drug in someone already losing strength "might be inducing frailty" [4]. That concern is his view and was not itself tested in the trial [1][4].

The trial also did not test other drugs such as semaglutide, so its results cannot be assumed for Ozempic or Wegovy [1]. Claims online that one GLP-1 drug causes more muscle loss than another were not tested here; chatbots asked such questions can produce confident but unsupported answers, as explained in AI Hallucinations Explained: Why Chatbots Make Things Up and How to Get Accurate Answers.

Should people on Mounjaro do weight training?

The trial shows that supervised resistance training reduced lean tissue loss and increased strength in this group, but whether and how someone should exercise is a decision for them and their clinician [1].

Professor Green said: "We now know that muscle loss can be reduced and strength increased when regular resistance training is used alongside tirzepatide treatment" [2]. He also said that the goal for people on weight-loss drugs should be better health and function, "not just a lower number on the scales" [2].

  • What was tested: progressive, supervised, centre-based resistance training three times a week, with strength testing by accredited clinical exercise physiologists [1].
  • What was not tested: unsupervised home exercise, other ages, people with diabetes or heart disease, or longer periods [1].
  • Prescription medicine: the NHS says tirzepatide is only available on prescription and warns that some websites sell fake weight-loss medicines [3]. Warning signs of fake online shops are covered in Black Friday Scams: How to Spot Fake Stores, Phishing, Payment Fraud.

This is not medical advice. Decisions about your own treatment belong with a qualified clinician who knows your history.

A tirzepatide-style injection pen kept in a fridge door beside a carton, representing prescription-only Mounjaro
The NHS says tirzepatide is prescription-only and warns about fake online sellers.

What comes next for GLP-1 drugs and muscle?

The authors call for studies on how lean mass differences affect long-term outcomes and on whether resistance training can be delivered in routine care [1].

  • Drug approaches: the paper notes that muscle-preserving drugs are being tested alongside incretin therapy, which it says overlooks a readily available non-drug option [1].
  • Healthspan: Green said combining weight-loss therapy with resistance exercise should in theory translate to a longer healthspan, which remains to be shown [2].
  • Public event: UWA's HealthSpan Institute is holding a free public lecture on obesity treatment on 26 November 2026 at the UWA Business School, with registration required [2].

How AI tools are being tested and regulated in clinical care, including obesity care, is explained in AI in Healthcare: What It Can Do Today, Where It Fails and How It Is Regulated.

T-REx trial: changes over 40 weeks on tirzepatide, with and without resistance training (Nature Medicine, 9 November 2026)
MeasureTirzepatide onlyTirzepatide + resistance trainingSource
Body weight−22.61 kg−22.28 kg[1]
Fat mass−17.19 kg−17.98 kg[1]
Lean soft tissue mass−4.67 kg−3.57 kg[1]
Appendicular lean mass−3.55 kg−2.92 kg[1]
Knee extension strength−4.42 kg+5.88 kg[1]
Lat pulldown strength−4.42 kg+8.58 kg[1]

Common mistakes

  • Thinking resistance training stopped all lean mass loss

    Fix: It reduced the loss from 4.67 kg to 3.57 kg; some loss remained [1].

  • Equating lean mass with muscle

    Fix: Lean mass also includes organs, bone, skin and water [2].

  • Expecting more weight loss with training

    Fix: Weight and fat loss were similar in both groups [1].

  • Applying results to every age and condition

    Fix: Participants were 50–70, sedentary and without diabetes or heart disease [1].

  • Buying tirzepatide online without a prescription

    Fix: The NHS warns that some websites sell fake weight-loss medicines [3].

Frequently asked questions

Does Mounjaro cause muscle loss?

It reduces lean soft tissue along with fat; untrained participants lost 4.67 kg of lean tissue in 40 weeks [1].

What did the T-REx trial find?

Resistance training cut lean tissue loss by 1.09 kg and raised strength, with similar weight loss [1].

Who was in the Mounjaro muscle trial?

120 men and postmenopausal women aged 50–70 with obesity or overweight, without diabetes [1].

What are the limits of the trial?

Small, 40 weeks, one centre, unblinded, and limited to sedentary 50- to 70-year-olds [1].

Should people on Mounjaro do weight training?

The trial supports supervised training in this group; individual decisions belong with a clinician [1].

What comes next for GLP-1 drugs and muscle?

Studies on long-term outcomes and routine-care feasibility are needed, the authors say [1].

Glossary

Tirzepatide
A weekly injected GLP-1/GIP agonist sold as Mounjaro, used for type 2 diabetes and obesity.
Lean soft tissue mass
Body mass excluding fat and bone mineral, including muscle, organs, skin and water.
Appendicular lean mass
Lean soft tissue in the arms and legs, mostly skeletal muscle.
Resistance training
Exercise that works muscles against a load, such as weights or machines.
DXA scan
A low-dose X-ray scan that measures fat, lean tissue and bone.
Sarcopenia
Age-related loss of muscle mass and strength.

Sources

  1. Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial Nature Medicine · 2026-11-09
  2. Resistance training key to maintaining muscle function during GLP-1 weight loss University of Western Australia · 2026-11-10
  3. Tirzepatide NHS · 2026-05-15
  4. Resistance training slashes muscle loss for GLP-1 patients: Study RACGP newsGP · 2026-11-10
  5. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) New England Journal of Medicine · 2022-06-04
Share this guide Telegram WhatsApp X
0 likes

Comments

Top comments

About the Pouyam Team Editorial policy

On Pouyam

Explore Pouyam

Guides are one corner of Pouyam. Here is where to go next.

Quick navigation